Global Pharma major Lupin Limited announced on 26 May 2025 that it has entered into a license and supply agreement with SteinCares, a leading specialty healthcare company in Latin America.
The agreement is for the commercialization of Lupin’s biosimilar ranibizumab across Latin America, excluding Mexico and Argentina.
Under the terms of the agreement, SteinCares will handle all regulatory filings, registrations, and commercialization of Ranibizumab in LATAM, while Lupin will be responsible for its manufacturing.
Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A (VEGF-A).
Its indications include the treatment of patients with Neovascular (Wet) Age-Related Macular Degeneration (AMD), Macular Edema Following Retinal Vein Occlusion (RVO), Diabetic Macular Edema (DME), Diabetic Retinopathy (DR), and Myopic Choroidal Neovascularization (mCNV).
Dr. Cyrus Karkaria, President Biotechnology, Lupin, commented that the partnership with SteinCares underscores Lupin's commitment to providing innovative, high-quality healthcare solutions and aims to transform the landscape of retinal care in Latin America.
Sebastián Katz, Chief Strategy Officer at SteinCares, stated that this partnership strengthens their portfolio and reinforces SteinCares’ position as a biosimilar powerhouse in Latin America, noting their consistent ability to be first to market products from highly regulated markets.